Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.

Eterna Therapeutics Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

CAMBRIDGE, MASS., JULY 09, 2025 (GLOBE NEWSWIRE) --  ERNEXA THERAPEUTICS (NASDAQ: ERNA), DEVELOPING INNOVATIVE CELL THERAPIES FOR THE TREATMENT OF ADVANCED CANCER AND AUTOIMMUNE DISEASE, TODAY ANNOUNCED THAT IT HAS REGAINED COMPLIANCE WITH NASDAQ FOR CONTINUED LISTING AND THAT ITS STOCK WILL CONTINUE TO TRADE ON THE NASDAQ STOCK MARKET.

ERNEXA THERAPEUTICS REGAINS COMPLIANCE WITH NASDAQ LISTING REQUIREMENTS

ADDITION OF DR. AMIR JAZAERI AND DR. ANNA JONSSON REFLECTS ERNEXA'S STRATEGIC FOCUS ON OVARIAN CANCER AND AUTOIMMUNE DISEASE PROGRAMS ADDITION OF DR. AMIR JAZAERI AND DR. ANNA JONSSON REFLECTS ERNEXA'S STRATEGIC FOCUS ON OVARIAN CANCER AND AUTOIMMUNE DISEASE PROGRAMS

ERNEXA THERAPEUTICS EXPANDS ADVISORY BOARD TO FORM INTEGRATED SCIENTIFIC AND MEDICAL ADVISORY BOARD AS IT PREPARES FOR CLINICAL DEVELOPMENT

STOCKHOLDER-APPROVED FINANCING BRINGS TOTAL GROSS PROCEEDS TO $7.1 MILLION; FUNDS TO SUPPORT WORKING CAPITAL INITIATIVES STOCKHOLDER-APPROVED FINANCING BRINGS TOTAL GROSS PROCEEDS TO $7.1 MILLION; FUNDS TO SUPPORT WORKING CAPITAL INITIATIVES

ERNEXA THERAPEUTICS SECURES $6 MILLION IN SECOND CLOSING UNDER SECURITIES PURCHASE AGREEMENT

CAMBRIDGE, MASS., JUNE 10, 2025 (GLOBE NEWSWIRE) -- ERNEXA THERAPEUTICS (NASDAQ: ERNA), DEVELOPING INNOVATIVE CELL THERAPIES FOR THE TREATMENT OF ADVANCED CANCER AND AUTOIMMUNE DISEASE, TODAY ANNOUNCED A REVERSE STOCK SPLIT OF ITS ISSUED AND OUTSTANDING SHARES OF COMMON STOCK, PAR VALUE $0.005 PER SHARE (THE COMMON STOCK), AT A RATIO OF 1-FOR-15, EFFECTIVE JUNE 12, 2025 AT 12:01 A.M. EASTERN TIME. THE COMPANY'S COMMON STOCK IS EXPECTED TO BEGIN TRADING ON A SPLIT-ADJUSTED BASIS WHEN THE MARKET OPENS ON JUNE 12, 2025, UNDER THE EXISTING TRADING SYMBOL ERNA.

ERNEXA THERAPEUTICS ANNOUNCES 1-FOR-15 REVERSE STOCK SPLIT

NEW DATA FINDS NOVEL CELL THERAPY SUCCESSFULLY CONVERTS COLD OVARIAN TUMORS INTO HOT, DEMONSTRATING POTENTIAL TO UNLOCK IMMUNE RESPONSE AND IMPROVE OUTCOMES NEW DATA FINDS NOVEL CELL THERAPY SUCCESSFULLY CONVERTS COLD OVARIAN TUMORS INTO HOT, DEMONSTRATING POTENTIAL TO UNLOCK IMMUNE RESPONSE AND IMPROVE OUTCOMES

ERNEXA THERAPEUTICS ANNOUNCES NEW DATA TO BE PRESENTED AT ASCO ANNUAL MEETING 2025

CAMBRIDGE, MASS., MAY 14, 2025 (GLOBE NEWSWIRE) -- ERNEXA THERAPEUTICS (NASDAQ: ERNA), DEVELOPING INNOVATIVE CELL THERAPIES FOR THE TREATMENT OF ADVANCED CANCER AND AUTOIMMUNE DISEASE, TODAY ANNOUNCED THE FORMATION OF ERNEXATX2, A WHOLLY OWNED SUBSIDIARY BASED IN TEXAS.

ERNEXA THERAPEUTICS ESTABLISHES TEXAS SUBSIDIARY TO SUPPORT CONTINUED DEVELOPMENT OF ERNA-101 AND FUTURE CLINICAL OPERATIONS

CAMBRIDGE, MASSACHUSETTS--(NEWSFILE CORP. - MAY 8, 2025) - ERNEXA THERAPEUTICS (NASDAQ: ERNA), TODAY ANNOUNCED ITS PARTICIPATION IN THE D. BORAL CAPITAL INAUGURAL GLOBAL CONFERENCE, TAKING PLACE MAY 14, 2025, AT THE PLAZA HOTEL IN NEW YORK CITY.

ERNEXA THERAPEUTICS ANNOUNCES PARTICIPATION IN THE D. BORAL CAPITAL INAUGURAL GLOBAL CONFERENCE

CAMBRIDGE, MASS., APRIL 29, 2025 (GLOBE NEWSWIRE) -- ERNEXA THERAPEUTICS (NASDAQ: ERNA), DEVELOPING INNOVATIVE CELL THERAPIES FOR THE TREATMENT OF ADVANCED CANCER AND AUTOIMMUNE DISEASE, PRESENTED NOTEWORTHY NEW DATA AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2025 IN CHICAGO ON APRIL 28.

ERNEXA THERAPEUTICS PRESENTED PROMISING DATA ON INNOVATIVE CELL THERAPY TREATMENT AT AACR ANNUAL MEETING 2025

CONFERENCE ATTENDEES WILL GET FIRST LOOK AT NEW DATA THAT SUPPORTS THE POTENTIAL OF ERNA-101 TO BOOST ANTI-TUMOR IMMUNITY IN OVARIAN CANCER CONFERENCE ATTENDEES WILL GET FIRST LOOK AT NEW DATA THAT SUPPORTS THE POTENTIAL OF ERNA-101 TO BOOST ANTI-TUMOR IMMUNITY IN OVARIAN CANCER

ERNEXA THERAPEUTICS ANNOUNCES NEW DATA TO BE PRESENTED AT AACR ANNUAL MEETING 2025

COMES ON THE HEELS OF COMPANY'S REBRANDING AND NEW STRATEGIC DIRECTION, ADVANCING ITS LEAD PROGRAM IN OVARIAN CANCER COMES ON THE HEELS OF COMPANY'S REBRANDING AND NEW STRATEGIC DIRECTION, ADVANCING ITS LEAD PROGRAM IN OVARIAN CANCER

Eterna Therapeutics Inc.

ERNA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Eterna Therapeutics Inc.

ERNA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ERNA